Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

Joaõ Agostinho MacHado-Neto, Bruna Alves Fenerich, Renata Scopim-Ribeiro, Christopher A. Eide, Juan Luiz Coelho-Silva, Carlos Roberto Porto Dechandt, Jaqueline Cristina Fernandes, Ana Paula Nunes Rodrigues Alves, Priscila Santos Scheucher, Belinda Pinto Simões, Luciane Carla Alberici, Lorena Lôbo De Figueiredo Pontes, Cristina E. Tognon, Brian Druker, Eduardo Magalhães Rego, Fabiola Traina

Research output: Contribution to journalArticle

Abstract

The recurrent gain-of-function JAK2V617F mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies. Metformin is a biguanide that exerts selective antineoplastic activity in hematological malignancies. In the present study, we investigate and compare effects of metformin and ruxolitinib alone and in combination on cell signaling and cellular functions in JAK2V617F-positive cells. In JAK2V617F-expressing cell lines, metformin treatment significantly reduced cell viability, cell proliferation, clonogenicity, and cellular oxygen consumption and delayed cell cycle progression. Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1/2 and p70S6K phosphorylation. Metformin plus ruxolitinib demonstrated more intense reduction of cell viability and induction of apoptosis compared to monotherapy. Notably, metformin reduced Ba/F3 JAK2V617F tumor burden and splenomegaly in Jak2V617F knock-in-induced MPN mice and spontaneous erythroid colony formation in primary cells from polycythemia vera patients. In conclusion, metformin exerts multitarget antileukemia activity in MPN: Downregulation of JAK2/STAT signaling and mitochondrial activity. Our exploratory study establishes novel molecular mechanisms of metformin and ruxolitinib action and provides insights for development of alternative/complementary therapeutic strategies for MPN.

Original languageEnglish (US)
Article number311
JournalCell Death and Disease
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Metformin
Neoplasms
Polycythemia Vera
Cell Survival
Cell Proliferation
70-kDa Ribosomal Protein S6 Kinases
Biguanides
Cyclin D1
Splenomegaly
Hematologic Neoplasms
Tumor Burden
Oxygen Consumption
Antineoplastic Agents
Intercellular Signaling Peptides and Proteins
Cell Cycle
Therapeutics
Down-Regulation
Phosphorylation
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

MacHado-Neto, J. A., Fenerich, B. A., Scopim-Ribeiro, R., Eide, C. A., Coelho-Silva, J. L., Dechandt, C. R. P., ... Traina, F. (2018). Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death and Disease, 9(3), [311]. https://doi.org/10.1038/s41419-017-0256-4

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. / MacHado-Neto, Joaõ Agostinho; Fenerich, Bruna Alves; Scopim-Ribeiro, Renata; Eide, Christopher A.; Coelho-Silva, Juan Luiz; Dechandt, Carlos Roberto Porto; Fernandes, Jaqueline Cristina; Rodrigues Alves, Ana Paula Nunes; Scheucher, Priscila Santos; Simões, Belinda Pinto; Alberici, Luciane Carla; De Figueiredo Pontes, Lorena Lôbo; Tognon, Cristina E.; Druker, Brian; Rego, Eduardo Magalhães; Traina, Fabiola.

In: Cell Death and Disease, Vol. 9, No. 3, 311, 01.03.2018.

Research output: Contribution to journalArticle

MacHado-Neto, JA, Fenerich, BA, Scopim-Ribeiro, R, Eide, CA, Coelho-Silva, JL, Dechandt, CRP, Fernandes, JC, Rodrigues Alves, APN, Scheucher, PS, Simões, BP, Alberici, LC, De Figueiredo Pontes, LL, Tognon, CE, Druker, B, Rego, EM & Traina, F 2018, 'Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms', Cell Death and Disease, vol. 9, no. 3, 311. https://doi.org/10.1038/s41419-017-0256-4
MacHado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP et al. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death and Disease. 2018 Mar 1;9(3). 311. https://doi.org/10.1038/s41419-017-0256-4
MacHado-Neto, Joaõ Agostinho ; Fenerich, Bruna Alves ; Scopim-Ribeiro, Renata ; Eide, Christopher A. ; Coelho-Silva, Juan Luiz ; Dechandt, Carlos Roberto Porto ; Fernandes, Jaqueline Cristina ; Rodrigues Alves, Ana Paula Nunes ; Scheucher, Priscila Santos ; Simões, Belinda Pinto ; Alberici, Luciane Carla ; De Figueiredo Pontes, Lorena Lôbo ; Tognon, Cristina E. ; Druker, Brian ; Rego, Eduardo Magalhães ; Traina, Fabiola. / Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. In: Cell Death and Disease. 2018 ; Vol. 9, No. 3.
@article{72b8a19d5e0647d5b2828a0cfb1ee6c9,
title = "Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms",
abstract = "The recurrent gain-of-function JAK2V617F mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies. Metformin is a biguanide that exerts selective antineoplastic activity in hematological malignancies. In the present study, we investigate and compare effects of metformin and ruxolitinib alone and in combination on cell signaling and cellular functions in JAK2V617F-positive cells. In JAK2V617F-expressing cell lines, metformin treatment significantly reduced cell viability, cell proliferation, clonogenicity, and cellular oxygen consumption and delayed cell cycle progression. Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1/2 and p70S6K phosphorylation. Metformin plus ruxolitinib demonstrated more intense reduction of cell viability and induction of apoptosis compared to monotherapy. Notably, metformin reduced Ba/F3 JAK2V617F tumor burden and splenomegaly in Jak2V617F knock-in-induced MPN mice and spontaneous erythroid colony formation in primary cells from polycythemia vera patients. In conclusion, metformin exerts multitarget antileukemia activity in MPN: Downregulation of JAK2/STAT signaling and mitochondrial activity. Our exploratory study establishes novel molecular mechanisms of metformin and ruxolitinib action and provides insights for development of alternative/complementary therapeutic strategies for MPN.",
author = "MacHado-Neto, {Joa{\~o} Agostinho} and Fenerich, {Bruna Alves} and Renata Scopim-Ribeiro and Eide, {Christopher A.} and Coelho-Silva, {Juan Luiz} and Dechandt, {Carlos Roberto Porto} and Fernandes, {Jaqueline Cristina} and {Rodrigues Alves}, {Ana Paula Nunes} and Scheucher, {Priscila Santos} and Sim{\~o}es, {Belinda Pinto} and Alberici, {Luciane Carla} and {De Figueiredo Pontes}, {Lorena L{\^o}bo} and Tognon, {Cristina E.} and Brian Druker and Rego, {Eduardo Magalh{\~a}es} and Fabiola Traina",
year = "2018",
month = "3",
day = "1",
doi = "10.1038/s41419-017-0256-4",
language = "English (US)",
volume = "9",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

AU - MacHado-Neto, Joaõ Agostinho

AU - Fenerich, Bruna Alves

AU - Scopim-Ribeiro, Renata

AU - Eide, Christopher A.

AU - Coelho-Silva, Juan Luiz

AU - Dechandt, Carlos Roberto Porto

AU - Fernandes, Jaqueline Cristina

AU - Rodrigues Alves, Ana Paula Nunes

AU - Scheucher, Priscila Santos

AU - Simões, Belinda Pinto

AU - Alberici, Luciane Carla

AU - De Figueiredo Pontes, Lorena Lôbo

AU - Tognon, Cristina E.

AU - Druker, Brian

AU - Rego, Eduardo Magalhães

AU - Traina, Fabiola

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The recurrent gain-of-function JAK2V617F mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies. Metformin is a biguanide that exerts selective antineoplastic activity in hematological malignancies. In the present study, we investigate and compare effects of metformin and ruxolitinib alone and in combination on cell signaling and cellular functions in JAK2V617F-positive cells. In JAK2V617F-expressing cell lines, metformin treatment significantly reduced cell viability, cell proliferation, clonogenicity, and cellular oxygen consumption and delayed cell cycle progression. Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1/2 and p70S6K phosphorylation. Metformin plus ruxolitinib demonstrated more intense reduction of cell viability and induction of apoptosis compared to monotherapy. Notably, metformin reduced Ba/F3 JAK2V617F tumor burden and splenomegaly in Jak2V617F knock-in-induced MPN mice and spontaneous erythroid colony formation in primary cells from polycythemia vera patients. In conclusion, metformin exerts multitarget antileukemia activity in MPN: Downregulation of JAK2/STAT signaling and mitochondrial activity. Our exploratory study establishes novel molecular mechanisms of metformin and ruxolitinib action and provides insights for development of alternative/complementary therapeutic strategies for MPN.

AB - The recurrent gain-of-function JAK2V617F mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies. Metformin is a biguanide that exerts selective antineoplastic activity in hematological malignancies. In the present study, we investigate and compare effects of metformin and ruxolitinib alone and in combination on cell signaling and cellular functions in JAK2V617F-positive cells. In JAK2V617F-expressing cell lines, metformin treatment significantly reduced cell viability, cell proliferation, clonogenicity, and cellular oxygen consumption and delayed cell cycle progression. Metformin reduced cyclin D1 expression and RB, STAT3, STAT5, ERK1/2 and p70S6K phosphorylation. Metformin plus ruxolitinib demonstrated more intense reduction of cell viability and induction of apoptosis compared to monotherapy. Notably, metformin reduced Ba/F3 JAK2V617F tumor burden and splenomegaly in Jak2V617F knock-in-induced MPN mice and spontaneous erythroid colony formation in primary cells from polycythemia vera patients. In conclusion, metformin exerts multitarget antileukemia activity in MPN: Downregulation of JAK2/STAT signaling and mitochondrial activity. Our exploratory study establishes novel molecular mechanisms of metformin and ruxolitinib action and provides insights for development of alternative/complementary therapeutic strategies for MPN.

UR - http://www.scopus.com/inward/record.url?scp=85042537484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042537484&partnerID=8YFLogxK

U2 - 10.1038/s41419-017-0256-4

DO - 10.1038/s41419-017-0256-4

M3 - Article

VL - 9

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 3

M1 - 311

ER -